Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon May 11, 2023 10:05am
84 Views
Post# 35442931

RE:RE:RE:RE: RE:RepliCel applies to TSX-V to extend warrants

RE:RE:RE:RE: RE:RepliCel applies to TSX-V to extend warrantsJC, yes that is the law regarding publicly traded companies. The the large position "insiders"  for the most part are the CEO and Directors.  Other large position shareholders that are not Directors but do have roles in the operation of Replicel: Kevin McElwee and Rolf Hoffmann.  You can' t tell me that these people listed above don't have more information regarding the Arbitration and the Dermal Injector than us 25%ers. Obviously these people have more information, they run the company.

The other large position shareholder (14,896,107 shares) that is not part of this group is Jamie Mackay.  I don't think it is a stretch that he may just have a little more ianformation than we do.

On May 8th more options granted:
Ben Austring: 250,000 Options granted
David Hall: 100,000 Options granted 
Peter Lowry: 100,000 Options granted
Peter Lewis: 75,000 Options granted
Andrew Schutte: 500,000 Options granted
Kevin McElwee: 250,000 Options granted

<< Previous
Bullboard Posts
Next >>